在2019冠状病毒病暴发流行期间感染并住院治疗的肾移植受者的临床特征与预后： 一项中国单中心队列研究

吕朵; 谢锡绍; 杨钦云; 陈芷珉; 刘光军; 彭文翰; 王仁定; 黄洪锋; 陈江华; 吴建永

doi:10.1631/jzus.B2300538

Your Location：

Home >

Browse articles >

在2019冠状病毒病暴发流行期间感染并住院治疗的肾移植受者的临床特征与预后：一项中国单中心队列研究

Scan for full text

文章被引用时，请邮件提醒。

Submit

Research Article | Updated：2024-06-24

在2019冠状病毒病暴发流行期间感染并住院治疗的肾移植受者的临床特征与预后：一项中国单中心队列研究
Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study
浙江大学学报（英文版）（B辑：生物医学和生物技术） 2024年25卷第6期页码：529-540
Affiliations：

1.Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2.Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China
3.Kidney Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
4.Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province, Hangzhou 310003, China
5.Institute of Nephrology, Zhejiang University, Hangzhou 310003, China
6.Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou 310003, China
7.The Third Grade Laboratory under the National State, Administration of Traditional Chinese Medicine, Hangzhou 310003, China
8.Information Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Funds：

the National Natural Science Foundation of China(2022YFC82200842);the Zhejiang Provincial Natural Science Foundation of China(LQ22H050004)
DOI：10.1631/jzus.B2300538
中图分类号：
CSTR：
纸质出版日期： 2024-06-15 ，

收稿日期： 2023-07-31 ，

修回日期： 2023-11-22 ，

吕朵,谢锡绍,杨钦云等.在2019冠状病毒病暴发流行期间感染并住院治疗的肾移植受者的临床特征与预后：一项中国单中心队列研究[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2024,25(06):529-540.

Duo LV, Xishao XIE, Qinyun YANG, et al. Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2024,25(6):529-540.
吕朵,谢锡绍,杨钦云等.在2019冠状病毒病暴发流行期间感染并住院治疗的肾移植受者的临床特征与预后：一项中国单中心队列研究[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2024,25(06):529-540. DOI： 10.1631/jzus.B2300538.

Duo LV, Xishao XIE, Qinyun YANG, et al. Clinical characteristics and outcomes of hospitalized kidney transplant recipients with COVID-19 infection in China during the Omicron wave: a single-center cohort study[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2024,25(6):529-540. DOI： 10.1631/jzus.B2300538.

摘要

2022年12月2019冠状病毒病（COVID-19）在中国出现短期的暴发流行，大量肾移植受者在感染COVID-19后需住院治疗。本研究回顾分析了在2022年12月16日至2023年1月31日期间感染COVID-19并在浙江大学医学院附属第一医院住院治疗的肾移植受者的临床特征和预后，随访截至2023年3月31日。本研究共纳入324名患者，其中位年龄为49岁，从出现症状到入院的中位时间为13天。分别有67例（20.7%）、11例（3.4%）和148例（45.7%）患者接受了莫那匹韦、阿兹夫定和奈玛特韦/利托那韦治疗，29例（9.0%）患者接受了多种抗病毒药物治疗，48例（14.8%）接受了托珠单抗治疗，53例（16.4%）接受了巴瑞替尼治疗。其中，81例（25.0%）发生急性肾损伤（AKI），39例（12.0%）转入ICU治疗，55例（17.0%）发生真菌感染，50例（15.4%）最终发生移植肾失功。患者的28天死亡率为9.0%，截至随访终点时共有42例（13.0%）患者死亡。多因素Cox回归分析显示合并脑血管疾病、AKI出现、白介素-6（IL-6）水平大于6.8 pg/mL、每日平均糖皮质激素剂量大于50 mg以及真菌感染等因素与住院患者死亡风险增加相关。结果表明，感染COVID-19后需住院治疗的肾移植受者死亡率很高。此外，服用免疫调节剂或过迟应用抗病毒药物，并不能提高患者生存率，而且大剂量的糖皮质激素使用则会增加死亡风险。

Abstract

Background

Following the short-term outbreak of coronavirus disease 2019 (COVID-19) in December 2022 in China

clinical data on kidney transplant recipients (KTRs) with COVID-19 are lacking.

Methods

We conducted a single-center retrospective study to describe the clinical features

complications

and mortality rates of hospitalized KTRs infected with COVID-19 between Dec. 16

2022 and Jan. 31

2023. The patients were followed up until Mar. 31

2023.

Results

A total of 324 KTRs with COVID-19 were included. The median age was 49 years. The median time between the onset of symptoms and admission was 13 d. Molnupiravir

azvudine

and nirmatrelvir/ritonavir were administered to 67 (20.7%)

11 (3.4%)

and 148 (45.7%) patients

respectively. Twenty-nine (9.0%) patients were treated with more than one antiviral agent. Forty-eight (14.8%) patients were treated with tocilizumab and 53 (16.4%) patients received baricitinib therapy. The acute kidney injury (AKI) occurred in 81 (25.0%) patients and 39 (12.0%) patients were admitted to intensive care units. Fungal infections were observed in 55 (17.0%) patients. Fifty (15.4%) patients lost their graft. The 28-d mortality rate of patients was 9.0% and 42 (13.0%) patients died by the end of follow-up. Multivariate Cox regression analysis identified that cerebrovascular disease

AKI incidence

interleukin (IL)‍-6 level of >6.8 pg/mL

daily dose of corticosteroids of >50 mg

and fungal infection were all associated with an increased risk of death for hospitalized patients.

Conclusions

Our findings demonstrate that hospitalized KTRs with COVID-19 are at high risk of mortality. The administration of immunomodulators or the late application of antiviral drugs does not improve patient survival

while higher doses of corticosteroids may increase the death risk.

关键词

2019冠状病毒病（COVID-19）肾移植住院治疗死亡率

Keywords

Coronavirus disease 2019 (COVID-19)Kidney transplantHospitalizationMortality

references

Ahmad FB, Cisewski JA, Xu JQ, et al., 2023. COVID-19 mortality update – United States, 2022. MMWR Morb Mortal Wkly Rep, 72(18):493-496. https://doi.org/10.15585/mmwr.mm7218a4https://doi.org/10.15585/mmwr.mm7218a4

Avery RK, 2022. Update on COVID-19 therapeutics for solid organ transplant recipients, including the omicron surge. Transplantation, 106(8):1528-1537. https://doi.org/10.1097/TP.0000000000004200https://doi.org/10.1097/TP.0000000000004200

Azzi Y, Bartash R, Scalea J, et al., 2021. COVID-19 and solid organ transplantation: a review article. Transplantation, 105(1):37-55. https://doi.org/10.1097/TP.0000000000003523https://doi.org/10.1097/TP.0000000000003523

Berger B, Hazzan M, Kamar N, et al., 2022. Absence of mortality differences between the first and second COVID-19 waves in kidney transplant recipients. Kidney Int Rep, 7(12):2617-2629. https://doi.org/10.1016/j.ekir.2022.09.007https://doi.org/10.1016/j.ekir.2022.09.007

Bernal E, Gimeno L, Alcaraz MJ, et al., 2021. Activating killer-cell immunoglobulin-like receptors are associated with the severity of coronavirus disease 2019. J Infect Dis, 224(2):229-240. https://doi.org/10.1093/infdis/jiab228https://doi.org/10.1093/infdis/jiab228

Caillard S, Anglicheau D, Matignon M, et al., 2020. An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. Kidney Int, 98(6):1549-1558. https://doi.org/10.1016/j.kint.2020.08.005https://doi.org/10.1016/j.kint.2020.08.005

Chan L, Chaudhary K, Saha A, et al., 2021. AKI in hospitalized patients with COVID-19. J Am Soc Nephrol, 32(1):151-160. https://doi.org/10.1681/ASN.2020050615https://doi.org/10.1681/ASN.2020050615

Chaudhuri D, Sasaki K, Karkar A, et al., 2021. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med, 47(5):521-537. https://doi.org/10.1007/s00134-021-06394-2https://doi.org/10.1007/s00134-021-06394-2

COVID-19 Excess Mortality Collaborators, 2022. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet, 399(10334):1513-1536. https://doi.org/10.1016/S0140-6736(21)02796-3https://doi.org/10.1016/S0140-6736(21)02796-3

Daniel E, Sekulic M, Kudose S, et al., 2021. Kidney allograft biopsy findings after COVID-19. Am J Transplant, 21(12):4032-4042. https://doi.org/10.1111/ajt.16804https://doi.org/10.1111/ajt.16804

Daoud A, Alqassieh A, Alkhader D, et al., 2021. Immunosuppression in kidney transplant recipients with COVID-19 infection – where do we stand and where are we heading? Ren Fail, 43(1):273-280. https://doi.org/10.1080/0886022X.2021.1876730https://doi.org/10.1080/0886022X.2021.1876730

Fang XY, Li S, Yu H, et al., 2020. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging, 12(13):‍‍‍12493-12503. https://doi.org/10.18632/aging.103579https://doi.org/10.18632/aging.103579

Farkash EA, Wilson AM, Jentzen JM, 2020. Ultrastructural evidence for direct renal infection with SARS-CoV-2. J Am Soc Nephrol, 31(8):1683-1687. https://doi.org/10.1681/ASN.2020040432https://doi.org/10.1681/ASN.2020040432

Favà A, Cucchiari D, Montero N, et al., 2020. Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: a multicentric cohort study. Am J Transplant, 20(11):3030-3041. https://doi.org/10.1111/ajt.16246https://doi.org/10.1111/ajt.16246

Gangneux JP, Dannaoui E, Fekkar A, et al., 2022. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med, 10(2):180-190. https://doi.org/10.1016/S2213-2600(21)00442-2https://doi.org/10.1016/S2213-2600(21)00442-2

Gérard AO, Barbosa S, Anglicheau D, et al., 2022. Association between maintenance immunosuppressive regimens and COVID-19 mortality in kidney transplant recipients. Transplantation, 106(10):2063-2067. https://doi.org/10.1097/TP.0000000000004254https://doi.org/10.1097/TP.0000000000004254

Gupta S, Wang W, Hayek SS, et al., 2021. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med, 181(1):41-51. https://doi.org/10.1001/jamainternmed.2020.6252https://doi.org/10.1001/jamainternmed.2020.6252

Hajibaratali B, Amini H, Dalili N, et al., 2023. Clinical outcomes of kidney recipients with COVID-19 (COVID-19 in kidney recipients). Transpl Immunol, 76:101772. https://doi.org/10.1016/j.trim.2022.101772https://doi.org/10.1016/j.trim.2022.101772

Hartzell S, Bin S, Benedetti C, et al., 2020. Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients. Am J Transplant, 20(11):3149-3161. https://doi.org/10.1111/ajt.16261https://doi.org/10.1111/ajt.16261

Jimeno S, Ventura PS, Castellano JM, et al., 2021. Prognostic implications of neutrophil-lymphocyte ratio in COVID-19. Eur J Clin Invest, 51(1):e13404. https://doi.org/10.1111/eci.13404https://doi.org/10.1111/eci.13404

Klopfenstein T, Gendrin V, Kadiane-Oussou NJ, et al., 2022. Tocilizumab in COVID-19 pneumonia: practical proposals based on a narrative review of randomised trials. Rev Med Virol, 32(1):e2239. https://doi.org/10.1002/rmv.2239https://doi.org/10.1002/rmv.2239

Kremer D, Pieters TT, Verhaar MC, et al., 2021. A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: lessons to be learned. Am J Transplant, 21(12):3936-3945. https://doi.org/10.1111/ajt.16742https://doi.org/10.1111/ajt.16742

Kronbichler A, Gauckler P, Windpessl M, et al., 2020. COVID-19: implications for immunosuppression in kidney disease and transplantation. Nat Rev Nephrol, 16(7):365-367. https://doi.org/10.1038/s41581-020-0305-6https://doi.org/10.1038/s41581-020-0305-6

Mahalingasivam V, Su GB, Iwagami M, et al., 2022. COVID-19 and kidney disease: insights from epidemiology to inform clinical practice. Nat Rev Nephrol, 18(8):485-498. https://doi.org/10.1038/s41581-022-00570-3https://doi.org/10.1038/s41581-022-00570-3

Mallhi TH, Khan YH, Alzarea AI, et al., 2022. Incidence, risk factors and outcomes of acute kidney injury among COVID-19 patients: a systematic review of systematic reviews. Front Med (Lausanne), 9:973030. https://doi.org/10.3389/fmed.2022.973030https://doi.org/10.3389/fmed.2022.973030

Masset C, Gautier-Vargas G, Cantarovich D, et al., 2022. Occurrence of de novo donor-specific antibodies after COVID-19 in kidney transplant recipients is low despite immunosuppression modulation. Kidney Int Rep, 7(5):983-992. https://doi.org/10.1016/j.ekir.2022.01.1072https://doi.org/10.1016/j.ekir.2022.01.1072

Mendoza MA, Ranganath N, Chesdachai S, et al., 2023. Immunomodulators for severe coronavirus disease-2019 in transplant patients: do they increase the risk of secondary infection? Transpl Infect Dis, 25(2):e14050. https://doi.org/10.1111/tid.14050https://doi.org/10.1111/tid.14050

Nab L, Parker EPK, Andrews CD, et al., 2023. Changes in COVID-19-related mortality across key demographic and clinical subgroups in England from 2020 to 2022: a retrospective cohort study using the OpenSAFELY platform. Lancet Public Health, 8(5):e364-e377. https://doi.org/10.1016/S2468-2667(23)00079-8https://doi.org/10.1016/S2468-2667(23)00079-8

Nadim MK, Forni LG, Mehta RL, et al., 2020. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol, 16(12):747-764. https://doi.org/10.1038/s41581-020-00356-5https://doi.org/10.1038/s41581-020-00356-5

National Institutes of Health (US), 2021. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. National Institutes of Health (US), Bethesda, USA. https://pubmed.ncbi.nlm.nih.gov/34003615https://pubmed.ncbi.nlm.nih.gov/34003615

Ng JH, Hirsch JS, Hazzan A, et al., 2021. Outcomes among patients hospitalized with COVID-19 and acute kidney injury. Am J Kidney Dis, 77(2):204-215.e1. https://doi.org/10.1053/j.ajkd.2020.09.002https://doi.org/10.1053/j.ajkd.2020.09.002

Nimmo A, Gardiner D, Ushiro-Lumb I, et al., 2022. The global impact of COVID-19 on solid organ transplantation: two years into a pandemic. Transplantation, 106(7):1312-1329. https://doi.org/10.1097/TP.0000000000004151https://doi.org/10.1097/TP.0000000000004151

Pereira MR, Aversa MM, Farr MA, et al., 2020. Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. Am J Transplant, 20(11):‍‍3198-3205. https://doi.org/10.1111/ajt.16314https://doi.org/10.1111/ajt.16314

Pérez-Sáez MJ, Blasco M, Redondo-Pachón D, et al., 2020. Use of tocilizumab in kidney transplant recipients with COVID-19. Am J Transplant, 20(11):3182-3190. https://doi.org/10.1111/ajt.16192https://doi.org/10.1111/ajt.16192

RECOVERY Collaborative Group, 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 397(10285):1637-1645. https://doi.org/10.1016/S0140-6736(21)00676-0https://doi.org/10.1016/S0140-6736(21)00676-0

RECOVERY Collaborative Group, 2022. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet, 400:359-368. https://doi.org/10.1016/S0140-6736(22)01109-6https://doi.org/10.1016/S0140-6736(22)01109-6

RECOVERY Collaborative Group, 2023. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 401(10387):1499-1507. https://doi.org/10.1016/S0140-6736(23)00510-Xhttps://doi.org/10.1016/S0140-6736(23)00510-X

Richier Q, Jachiet V, Bonnemains V, et al., 2022. Tocilizumab and COVID-19: timing of administration assessment. Infect Dis Now, 52(1):31-34. https://doi.org/10.1016/j.idnow.2021.06.304https://doi.org/10.1016/j.idnow.2021.06.304

Ronco C, Reis T, Husain-Syed F, 2020. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med, 8(7):738-742. https://doi.org/10.1016/S2213-2600(20)30229-0https://doi.org/10.1016/S2213-2600(20)30229-0

Saravolatz LD, Depcinski S, Sharma M, 2023. Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis, 76(1):165-171. https://doi.org/10.1093/cid/ciac180https://doi.org/10.1093/cid/ciac180

Singh AK, Oks M, Husk G, et al., 2021. Impact of timing of tocilizumab use in hospitalized patients with SARS-CoV-2 infection. Respir Care, 66(12):1805-1814. https://doi.org/10.4187/respcare.08779https://doi.org/10.4187/respcare.08779

Su H, Yang M, Wan C, et al., 2020. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int, 98(1):219-227. https://doi.org/10.1016/j.kint.2020.04.003https://doi.org/10.1016/j.kint.2020.04.003

Talic S, Shah S, Wild H, et al., 2021. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2 transmission, and covid-19 mortality: systematic review and meta-analysis. BMJ, 375:e068302. https://doi.org/10.1136/bmj-2021-068302https://doi.org/10.1136/bmj-2021-068302

Tan BWL, Tan BWQ, Tan ALM, et al., 2023. Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: an international multi-centre observational cohort study. eClinicalMedicine, 55:101724. https://doi.org/10.1016/j.eclinm.2022.101724https://doi.org/10.1016/j.eclinm.2022.101724

Tatum D, Taghavi S, Houghton A, et al., 2020. Neutrophil-to-lymphocyte ratio and outcomes in Louisiana COVID-19 patients. Shock, 54(5):652-658. https://doi.org/10.1097/SHK.0000000000001585https://doi.org/10.1097/SHK.0000000000001585

Tu JY, Mo XQ, Zhang XD, et al., 2022. Effects of different corticosteroid therapy on severe COVID-19 patients: a meta-analysis of randomized controlled trials. Expert Rev Respir Med, 16(1):79-89. https://doi.org/10.1080/17476348.2021.1983429https://doi.org/10.1080/17476348.2021.1983429

van Grootveld R, van der Beek MT, Janssen NAF, et al., 2023. Incidence, risk factors and pre-emptive screening for COVID-19 associated pulmonary aspergillosis in an era of immunomodulant therapy. J Crit Care, 76:154272. https://doi.org/10.1016/j.jcrc.2023.154272https://doi.org/10.1016/j.jcrc.2023.154272

Wagner C, Griesel M, Mikolajewska A, et al., 2021. Systemic corticosteroids for the treatment of COVID-19. Cochrane Database Syst Rev, 8(8):CD014963. https://doi.org/10.1002/14651858.CD014963https://doi.org/10.1002/14651858.CD014963

Wang AX, Koff A, Hao DN, et al., 2022. Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: early experience in four SARS-CoV-2 infected kidney transplant recipients. Am J Transplant, 22(8):2117-2119. https://doi.org/10.1111/ajt.16997https://doi.org/10.1111/ajt.16997

Weiss A, Hendrickx R, Stensgaard E, et al., 2023. Kidney transplant and dialysis patients remain at increased risk for succumbing to COVID-19. Transplantation, 107(5):1136-1138. https://doi.org/10.1097/TP.0000000000004462https://doi.org/10.1097/TP.0000000000004462

Willicombe M, Thomas D, McAdoo S, 2020. COVID-19 and calcineurin inhibitors: should they get left out in the storm? J Am Soc Nephrol, 31(6):1145-1146. https://doi.org/10.1681/ASN.2020030348https://doi.org/10.1681/ASN.2020030348

Zhang WJ, Han F, Wu XF, et al., 2022. COVID-19 in the immunocompromised population: data from renal allograft recipients throughout full cycle of the outbreak in Hubei province, China. Chin Med J, 135(2):228-230. https://doi.org/10.1097/CM9.0000000000001538https://doi.org/10.1097/CM9.0000000000001538

Zhou ZF, Kuang H, Ma YX, et al., 2021. Application of extracorporeal therapies in critically ill COVID-19 patients. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(9):‍‍701-717. https://doi.org/10.1631/jzus.B2100344https://doi.org/10.1631/jzus.B2100344

Zhu L, Gong NQ, Liu B, et al., 2020. Coronavirus disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China. Eur Urol, 77(6):748-754. https://doi.org/10.1016/j.eururo.2020.03.039https://doi.org/10.1016/j.eururo.2020.03.039

浏览量

Downloads

CSCD

工具集

关联资源

Multi-biomarker strategy for prediction of myocardial dysfunction and mortality in sepsis

Within-litter variation in birth weight: impact of nutritional status in the sow

Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy

Mental health, health-related quality of life, and lung function after hospital discharge in healthcare workers with severe COVID-19: a cohort study from China

Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis